+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Future of Coronary Artery Disease (CAD)/Ischemic Heart Disease R&D Pipeline Drugs and Companies- Analysis of Global Coronary Artery Disease (CAD) Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4745191
  • Report
  • January 2019
  • Region: Global
  • 120 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • advanceCor GmbH
  • AstraZeneca Plc
  • CSL Ltd
  • Idorsia Ltd
  • Merck & Co Inc
  • Recardio, Inc.
  • MORE
The global demand for Coronary Artery Disease (CAD) (Ischemic Heart Disease) treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline companies from advancing their products into Phase 3 or Phase 4.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Report Description

The H1- 2019 pipeline review report on Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline compounds.

The Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline guide presents information on all active drugs currently being developed for Coronary Artery Disease (CAD) (Ischemic Heart Disease). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Coronary Artery Disease (CAD) (Ischemic Heart Disease) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Coronary Artery Disease (CAD) (Ischemic Heart Disease) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline report includes
  • An overview of Coronary Artery Disease (CAD) (Ischemic Heart Disease) disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of pipeline compounds
  • Company wise list of pipeline compounds
  • Mechanism of Action wise pipeline compounds
For each pipeline product, the following details are provided
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into the market through in-depth strategic analysis review
  • Know the list of companies participating in global Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • advanceCor GmbH
  • AstraZeneca Plc
  • CSL Ltd
  • Idorsia Ltd
  • Merck & Co Inc
  • Recardio, Inc.
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology

3. Executive Summary
3.1 Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline, H1- 2019
3.5 Mechanism of Action wise Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Candidates

4. advanceCor GmbH Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
4.1 advanceCor GmbH Business Profile
4.2 advanceCor GmbH Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5. AngioSoma Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
5.1 AngioSoma Inc Business Profile
5.2 AngioSoma Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6. APT Therapeutics Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
6.1 APT Therapeutics Inc Business Profile
6.2 APT Therapeutics Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7. Ascendia Pharmaceuticals LLC Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
7.1 Ascendia Pharmaceuticals LLC Business Profile
7.2 Ascendia Pharmaceuticals LLC Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8. Asdera Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
8.1 Asdera Business Profile
8.2 Asdera Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9. AstraZeneca Plc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
9.1 AstraZeneca Plc Business Profile
9.2 AstraZeneca Plc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10. Bayer HealthCare Pharmaceuticals Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
10.1 Bayer HealthCare Pharmaceuticals Business Profile
10.2 Bayer HealthCare Pharmaceuticals Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11. Bio-Thera Solutions Ltd Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
11.1 Bio-Thera Solutions Ltd Business Profile
11.2 Bio-Thera Solutions Ltd Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12. Biscayne Pharmaceuticals Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
12.1 Biscayne Pharmaceuticals Inc Business Profile
12.2 Biscayne Pharmaceuticals Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
12.2.1 Drug Snapshot
12.2.1.1 Originator
12.2.1.2 Collaborator/Co-Developer
12.2.1.3 Route of Administration
12.2.1.4 Orphan Drug/Fast Track/Special Designation
12.2.1.5 Area
12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13. Bracco Imaging S.p.A. Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
13.1 Bracco Imaging S.p.A. Business Profile
13.2 Bracco Imaging S.p.A. Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
13.2.1 Drug Snapshot
13.2.1.1 Originator
13.2.1.2 Collaborator/Co-Developer
13.2.1.3 Route of Administration
13.2.1.4 Orphan Drug/Fast Track/Special Designation
13.2.1.5 Area
13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14. Capricor Therapeutics Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
14.1 Capricor Therapeutics Inc Business Profile
14.2 Capricor Therapeutics Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
14.2.1 Drug Snapshot
14.2.1.1 Originator
14.2.1.2 Collaborator/Co-Developer
14.2.1.3 Route of Administration
14.2.1.4 Orphan Drug/Fast Track/Special Designation
14.2.1.5 Area
14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15. CardioVascular BioTherapeutics Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
15.1 CardioVascular BioTherapeutics Inc Business Profile
15.2 CardioVascular BioTherapeutics Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
15.2.1 Drug Snapshot
15.2.1.1 Originator
15.2.1.2 Collaborator/Co-Developer
15.2.1.3 Route of Administration
15.2.1.4 Orphan Drug/Fast Track/Special Designation
15.2.1.5 Area
15.2.1.6 Type of Molecular Entity
15.3 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16. CSL Ltd Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
16.1 CSL Ltd Business Profile
16.2 CSL Ltd Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
16.2.1 Drug Snapshot
16.2.1.1 Originator
16.2.1.2 Collaborator/Co-Developer
16.2.1.3 Route of Administration
16.2.1.4 Orphan Drug/Fast Track/Special Designation
16.2.1.5 Area
16.2.1.6 Type of Molecular Entity
16.3 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments

17. DalCor Pharmaceuticals Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
17.1 DalCor Pharmaceuticals Inc Business Profile
17.2 DalCor Pharmaceuticals Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
17.2.1 Drug Snapshot
17.2.1.1 Originator
17.2.1.2 Collaborator/Co-Developer
17.2.1.3 Route of Administration
17.2.1.4 Orphan Drug/Fast Track/Special Designation
17.2.1.5 Area
17.2.1.6 Type of Molecular Entity
17.3 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments

18. Diapin Therapeutics LLC Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
18.1 Diapin Therapeutics LLC Business Profile
18.2 Diapin Therapeutics LLC Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
18.2.1 Drug Snapshot
18.2.1.1 Originator
18.2.1.2 Collaborator/Co-Developer
18.2.1.3 Route of Administration
18.2.1.4 Orphan Drug/Fast Track/Special Designation
18.2.1.5 Area
18.2.1.6 Type of Molecular Entity
18.3 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments

19. Gilead Sciences Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
19.1 Gilead Sciences Inc Business Profile
19.2 Gilead Sciences Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
19.2.1 Drug Snapshot
19.2.1.1 Originator
19.2.1.2 Collaborator/Co-Developer
19.2.1.3 Route of Administration
19.2.1.4 Orphan Drug/Fast Track/Special Designation
19.2.1.5 Area
19.2.1.6 Type of Molecular Entity
19.3 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments

20. Hemostemix Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
20.1 Hemostemix Inc Business Profile
20.2 Hemostemix Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
20.2.1 Drug Snapshot
20.2.1.1 Originator
20.2.1.2 Collaborator/Co-Developer
20.2.1.3 Route of Administration
20.2.1.4 Orphan Drug/Fast Track/Special Designation
20.2.1.5 Area
20.2.1.6 Type of Molecular Entity
20.3 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments

21. Idorsia Ltd Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
21.1 Idorsia Ltd Business Profile
21.2 Idorsia Ltd Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
21.2.1 Drug Snapshot
21.2.1.1 Originator
21.2.1.2 Collaborator/Co-Developer
21.2.1.3 Route of Administration
21.2.1.4 Orphan Drug/Fast Track/Special Designation
21.2.1.5 Area
21.2.1.6 Type of Molecular Entity
21.3 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments

22. Jaan Biotherapeutics LLC Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
22.1 Jaan Biotherapeutics LLC Business Profile
22.2 Jaan Biotherapeutics LLC Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
22.2.1 Drug Snapshot
22.2.1.1 Originator
22.2.1.2 Collaborator/Co-Developer
22.2.1.3 Route of Administration
22.2.1.4 Orphan Drug/Fast Track/Special Designation
22.2.1.5 Area
22.2.1.6 Type of Molecular Entity
22.3 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments

23. LipimetiX Development Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
23.1 LipimetiX Development Inc Business Profile
23.2 LipimetiX Development Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
23.2.1 Drug Snapshot
23.2.1.1 Originator
23.2.1.2 Collaborator/Co-Developer
23.2.1.3 Route of Administration
23.2.1.4 Orphan Drug/Fast Track/Special Designation
23.2.1.5 Area
23.2.1.6 Type of Molecular Entity
23.3 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments

24. MedImmune LLC Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
24.1 MedImmune LLC Business Profile
24.2 MedImmune LLC Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
24.2.1 Drug Snapshot
24.2.1.1 Originator
24.2.1.2 Collaborator/Co-Developer
24.2.1.3 Route of Administration
24.2.1.4 Orphan Drug/Fast Track/Special Designation
24.2.1.5 Area
24.2.1.6 Type of Molecular Entity
24.3 Current Status
24.4 Drug Overview
24.5 Drug Mechanism of Action
24.6 Clinical/Pre-clinical Trial Details
24.7 Latest Drug Developments

25. Merck & Co Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
25.1 Merck & Co Inc Business Profile
25.2 Merck & Co Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
25.2.1 Drug Snapshot
25.2.1.1 Originator
25.2.1.2 Collaborator/Co-Developer
25.2.1.3 Route of Administration
25.2.1.4 Orphan Drug/Fast Track/Special Designation
25.2.1.5 Area
25.2.1.6 Type of Molecular Entity
25.3 Current Status
25.4 Drug Overview
25.5 Drug Mechanism of Action
25.6 Clinical/Pre-clinical Trial Details
25.7 Latest Drug Developments

26. Orion Corporation Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
26.1 Orion Corporation Business Profile
26.2 Orion Corporation Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
26.2.1 Drug Snapshot
26.2.1.1 Originator
26.2.1.2 Collaborator/Co-Developer
26.2.1.3 Route of Administration
26.2.1.4 Orphan Drug/Fast Track/Special Designation
26.2.1.5 Area
26.2.1.6 Type of Molecular Entity
26.3 Current Status
26.4 Drug Overview
26.5 Drug Mechanism of Action
26.6 Clinical/Pre-clinical Trial Details
26.7 Latest Drug Developments

27. Pharmahungary Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
27.1 Pharmahungary Business Profile
27.2 Pharmahungary Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
27.2.1 Drug Snapshot
27.2.1.1 Originator
27.2.1.2 Collaborator/Co-Developer
27.2.1.3 Route of Administration
27.2.1.4 Orphan Drug/Fast Track/Special Designation
27.2.1.5 Area
27.2.1.6 Type of Molecular Entity
27.3 Current Status
27.4 Drug Overview
27.5 Drug Mechanism of Action
27.6 Clinical/Pre-clinical Trial Details
27.7 Latest Drug Developments

28. Proteon Therapeutics Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
28.1 Proteon Therapeutics Inc Business Profile
28.2 Proteon Therapeutics Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
28.2.1 Drug Snapshot
28.2.1.1 Originator
28.2.1.2 Collaborator/Co-Developer
28.2.1.3 Route of Administration
28.2.1.4 Orphan Drug/Fast Track/Special Designation
28.2.1.5 Area
28.2.1.6 Type of Molecular Entity
28.3 Current Status
28.4 Drug Overview
28.5 Drug Mechanism of Action
28.6 Clinical/Pre-clinical Trial Details
28.7 Latest Drug Developments

29. Recardio, Inc. Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
29.1 Recardio, Inc. Business Profile
29.2 Recardio, Inc. Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
29.2.1 Drug Snapshot
29.2.1.1 Originator
29.2.1.2 Collaborator/Co-Developer
29.2.1.3 Route of Administration
29.2.1.4 Orphan Drug/Fast Track/Special Designation
29.2.1.5 Area
29.2.1.6 Type of Molecular Entity
29.3 Current Status
29.4 Drug Overview
29.5 Drug Mechanism of Action
29.6 Clinical/Pre-clinical Trial Details
29.7 Latest Drug Developments

30. Resverlogix Corp Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
30.1 Resverlogix Corp Business Profile
30.2 Resverlogix Corp Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
30.2.1 Drug Snapshot
30.2.1.1 Originator
30.2.1.2 Collaborator/Co-Developer
30.2.1.3 Route of Administration
30.2.1.4 Orphan Drug/Fast Track/Special Designation
30.2.1.5 Area
30.2.1.6 Type of Molecular Entity
30.3 Current Status
30.4 Drug Overview
30.5 Drug Mechanism of Action
30.6 Clinical/Pre-clinical Trial Details
30.7 Latest Drug Developments

31. Reven Pharmaceuticals Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
31.1 Reven Pharmaceuticals Inc Business Profile
31.2 Reven Pharmaceuticals Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
31.2.1 Drug Snapshot
31.2.1.1 Originator
31.2.1.2 Collaborator/Co-Developer
31.2.1.3 Route of Administration
31.2.1.4 Orphan Drug/Fast Track/Special Designation
31.2.1.5 Area
31.2.1.6 Type of Molecular Entity
31.3 Current Status
31.4 Drug Overview
31.5 Drug Mechanism of Action
31.6 Clinical/Pre-clinical Trial Details
31.7 Latest Drug Developments

32. Servier Laboratories Limited Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
32.1 Servier Laboratories Limited Business Profile
32.2 Servier Laboratories Limited Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
32.2.1 Drug Snapshot
32.2.1.1 Originator
32.2.1.2 Collaborator/Co-Developer
32.2.1.3 Route of Administration
32.2.1.4 Orphan Drug/Fast Track/Special Designation
32.2.1.5 Area
32.2.1.6 Type of Molecular Entity
32.3 Current Status
32.4 Drug Overview
32.5 Drug Mechanism of Action
32.6 Clinical/Pre-clinical Trial Details
32.7 Latest Drug Developments

33. The Medicines Company Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
33.1 The Medicines Company Business Profile
33.2 The Medicines Company Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
33.2.1 Drug Snapshot
33.2.1.1 Originator
33.2.1.2 Collaborator/Co-Developer
33.2.1.3 Route of Administration
33.2.1.4 Orphan Drug/Fast Track/Special Designation
33.2.1.5 Area
33.2.1.6 Type of Molecular Entity
33.3 Current Status
33.4 Drug Overview
33.5 Drug Mechanism of Action
33.6 Clinical/Pre-clinical Trial Details
33.7 Latest Drug Developments

34. Vasade Biosciences Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
34.1 Vasade Biosciences Business Profile
34.2 Vasade Biosciences Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
34.2.1 Drug Snapshot
34.2.1.1 Originator
34.2.1.2 Collaborator/Co-Developer
34.2.1.3 Route of Administration
34.2.1.4 Orphan Drug/Fast Track/Special Designation
34.2.1.5 Area
34.2.1.6 Type of Molecular Entity
34.3 Current Status
34.4 Drug Overview
34.5 Drug Mechanism of Action
34.6 Clinical/Pre-clinical Trial Details
34.7 Latest Drug Developments

35. Verseon Corp Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
35.1 Verseon Corp Business Profile
35.2 Verseon Corp Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
35.2.1 Drug Snapshot
35.2.1.1 Originator
35.2.1.2 Collaborator/Co-Developer
35.2.1.3 Route of Administration
35.2.1.4 Orphan Drug/Fast Track/Special Designation
35.2.1.5 Area
35.2.1.6 Type of Molecular Entity
35.3 Current Status
35.4 Drug Overview
35.5 Drug Mechanism of Action
35.6 Clinical/Pre-clinical Trial Details
35.7 Latest Drug Developments

36. VESSL Therapeutics Ltd Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
36.1 VESSL Therapeutics Ltd Business Profile
36.2 VESSL Therapeutics Ltd Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
36.2.1 Drug Snapshot
36.2.1.1 Originator
36.2.1.2 Collaborator/Co-Developer
36.2.1.3 Route of Administration
36.2.1.4 Orphan Drug/Fast Track/Special Designation
36.2.1.5 Area
36.2.1.6 Type of Molecular Entity
36.3 Current Status
36.4 Drug Overview
36.5 Drug Mechanism of Action
36.6 Clinical/Pre-clinical Trial Details
36.7 Latest Drug Developments

37. ViroMed Co Ltd Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
37.1 ViroMed Co Ltd Business Profile
37.2 ViroMed Co Ltd Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
37.2.1 Drug Snapshot
37.2.1.1 Originator
37.2.1.2 Collaborator/Co-Developer
37.2.1.3 Route of Administration
37.2.1.4 Orphan Drug/Fast Track/Special Designation
37.2.1.5 Area
37.2.1.6 Type of Molecular Entity
37.3 Current Status
37.4 Drug Overview
37.5 Drug Mechanism of Action
37.6 Clinical/Pre-clinical Trial Details
37.7 Latest Drug Developments

38. XyloCor Therapeutics Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Details
38.1 XyloCor Therapeutics Inc Business Profile
38.2 XyloCor Therapeutics Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
38.2.1 Drug Snapshot
38.2.1.1 Originator
38.2.1.2 Collaborator/Co-Developer
38.2.1.3 Route of Administration
38.2.1.4 Orphan Drug/Fast Track/Special Designation
38.2.1.5 Area
38.2.1.6 Type of Molecular Entity
38.3 Current Status
38.4 Drug Overview
38.5 Drug Mechanism of Action
38.6 Clinical/Pre-clinical Trial Details
38.7 Latest Drug Developments

20. Latest Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Pipeline Developments, 2019

21. Appendix
21.1 About Us
21.2 Sources and Methodology
21.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • advanceCor GmbH
  • AngioSoma Inc
  • APT Therapeutics Inc
  • Ascendia Pharmaceuticals LLC
  • Asdera
  • AstraZeneca Plc
  • Bayer HealthCare Pharmaceuticals
  • Bio-Thera Solutions Ltd
  • Biscayne Pharmaceuticals Inc
  • Bracco Imaging S.p.A.
  • Capricor Therapeutics Inc
  • CardioVascular BioTherapeutics Inc
  • CSL Ltd
  • DalCor Pharmaceuticals Inc
  • Diapin Therapeutics LLC
  • Gilead Sciences Inc
  • Hemostemix Inc
  • Idorsia Ltd
  • Jaan Biotherapeutics LLC
  • LipimetiX Development Inc
  • MedImmune LLC
  • Merck & Co Inc
  • Orion Corporation
  • Pharmahungary
  • Proteon Therapeutics Inc
  • Recardio, Inc.
  • Resverlogix Corp
  • Reven Pharmaceuticals Inc
  • Servier Laboratories Limited
  • The Medicines Company
  • Vasade Biosciences
  • Verseon Corp
  • VESSL Therapeutics Ltd
  • ViroMed Co Ltd
  • XyloCor Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll